An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

Annals of Oncology

Volumn 19, Issue 1, 2008, Pages 92-98

  Van Cutsem, Eric ^a   Siena, S ^b   Humblet, Y ^c   Canon, J L ^d   Maurel, J ^e   Bajetta, E ^f   Neyns, B ^g   Kotasek, D ^h   Santoro, A ⁱ   Scheithauer, W ^j   Spadafora, S ^k   Amado, R G ^l   Hogan, N ^m   Peeters, M ⁿ  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d Centre Hospitalier Notre Dame et Reine Fabiola   (Belgium)

^e HOSPITAL CLÍNIC   (Spain)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^h Ashford Cancer Centre   (Australia)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k Sault Area Hospitals   (Canada)

^l AMGEN INC   (United States)

^m AMGEN LTD   (United Kingdom)

ⁿ GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Crossover; EGFr; Extension study; Fully human antibody; Metastatic colorectal cancer; Panitumumab

Indexed keywords

PANITUMUMAB;

ACNE; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN EXFOLIATION; TREATMENT RESPONSE;

EID: 38049044037     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm399     Document Type: Article

References (21)

1. World Health Organization. Facts about Cancer. Geneva, Switzerland: World Health Organization, 2007. http://www.who.int/mediacentre/ factsheets/fs297/en/index.html (22 February 2007, date last accessed).
2. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
3. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. McKay JA, Murray LJ, Curran S et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002; 38: 2258-2264.
6. Wan CW, McKnight MK, Brattain DE et al. Different epidermal growth factor growth responses and receptor levels in human colon carcinoma cell lines. Cancer Lett 1988; 43: 139-143.
7. Erbitux®. Prescribing Information. Branchburg, NJ: ImClone Systems Inc 2005.
8. Vectibix®. Prescribing Information. Thousand Oaks, CA: Amgen Inc 2006.
9. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
10. National Cancer Institute. Cancer Therapy Evaluaton Program CTC v2.0 and Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2007. http://ctep.cancer.gov/reporting/ ctc.html (26 February 2007, date last accessed).
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organizaton for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute, of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005; 304: 189-195.
13. Lofgren J, Dhandapani S, Pennucci J et al. Comparison of ELISA and Biacore assay for detection of anti-panitumumab antibodies in clinical studies. J Immunol 2007; 178: 7467-7472.
14. Berlin J, Neubauer M, Swanson P et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing>10% epidermal growth factor receptor (EGFr). J Clin Oncol ASCO Annual Meeting Proceedings Part I 2006; 24: (Abstr 3548).
15. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
16. Hecht JR, Mitchell E, Baranda J et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol ASCO Annual Meeting Proceedings Part I. 2006; 24: (Abstr 3547).
17. Hecht JR, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007.
18. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97: 1221-1224.
19. Agero AL, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-670.
20. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006; 29: 1-9.
21. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921.